Sign up to save your podcasts
Or
Share A Lackluster JPM and a Troubling future for Fate Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A Lackluster JPM and a Troubling future for Fate Therapeutics
This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
View all episodes
By Biotech Bros LLC.This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies.
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com